Lucknow, Nov. 14 -- Era University has developed an affordable testing device to detect asymmetric dimethylarginine (ADMA), a protein molecule linked to cardiovascular risk, using just two drops of blood. Researchers claim that high ADMA levels may indicate the risk of a heart attack 10-12 years in advance, according to a press release shared with the media on Friday. The research was presented at the 5th International Conference on Personalized Medicine (ISPMCon-2026), organised at Era University on Friday under the aegis of the Indian Society of Personalized Medicine. Vice-chancellor prof Farzana Mahdi said conventional heart-risk assessments mainly rely on cholesterol and lipid profile tests, which may not identify everyone at risk. She said the university had developed a method to detect ADMA, a marker that is not routinely checked through conventional screening. The research has been patented. The university has also partnered with Chennai-based Gene Aura Private Limited, led by Dr Janani Dakshinamurthy, to develop an affordable prototype test kit for wider public use. ADMA screening has already started at Era University. Prof Abbas Ali Mahdi said the initiative was part of the wider approach to personalised medicine, as the same medicine may produce different responses in different patients. Dr Shiraz Rizvi also spoke about the potential of the new testing technology. htc...